Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Tel Aviv Sourasky Medical Center

Status and phase: Unknown; Phase 2

Conditions: Central Serous Chorioretinopathy

Treatments: Drug: Brinzolamide Ophthalmic

Study type: Interventional

Funder types: Other

Identifiers

NCT03542006

0647-17

Details and patient eligibility

About

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Full description

Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors have been shown to be effective for the treatment of macular edema when administered orally, also for central serous chorioretinopathy. However, this treatment carries the risk of severe side effects.

The goal of this study is to examine the efficacy of the topical form of treatment of carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous chorioretinopathy.

Enrollment: 35 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4 months of follow-up
• Optical coherence tomography (OCT) shows foveal subretinal fluid
• Fluorescein angiography and indocyanine green confirm the diagnosis

Exclusion criteria

• Any other ophthalmic condition that may lead to subretinal fluid
• Choroidal neovascularization
• Myopia > -6D
• Previous treatment for CSC in the past 6 months
• Known allergy to fluorescein or indocyanin green
• Known allergy for brinzolamide
• Pregnancy, breast feeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

Topical brinzolamide

Experimental group

Description:

Brinzolamide ophthalmic, given bd for 3 months

Treatment:

Drug: Brinzolamide Ophthalmic